
    
      The drug being tested in this study is called TAK-906. TAK-906 is being tested in healthy
      participants to evaluate the effect of a PPI esomeprazole on the PK of TAK-906.

      The study will enroll approximately 12 participants. Participants will be assigned to the
      following treatment sequence:

      â€¢ TAK-906 25 mg; Esomeprazole 40 mg + TAK-906 25 mg

      All participants will be given an oral dose of TAK-906 and Esomeprazole.

      This single center trial will be conducted in the United States. The overall duration to
      participate in this study is 52 days. Participants will make visit to the clinic during
      Period 1 and Period 2 in addition to approximately 10 to 14 days after receiving their last
      dose of TAK-906 for a follow up assessment.
    
  